263 related articles for article (PubMed ID: 34100025)
1. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
Diefenbach C; Caro J; Koide A; Grossbard M; Goldberg JD; Raphael B; Hymes K; Moskovits T; Kreditor M; Kaminetzky D; Fleur-Lominy SS; Choi J; Thannickal SA; Stapleford KA; Koide S
medRxiv; 2021 Jun; ():. PubMed ID: 34100025
[TBL] [Abstract][Full Text] [Related]
2. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
4. Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA; Allen PB; Lechowicz MJ; Romancik JT; Ayers A; Leal A; O'Leary CB; Churnetski MC; Baird K; Kives M; Wrammert J; Nooka AK; Koff JL; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
Cancer Res Commun; 2022 Dec; 2(12):1684-1692. PubMed ID: 36644323
[TBL] [Abstract][Full Text] [Related]
5. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Induction of neutralizing antibodies in CLL patients after SARS-CoV-2 mRNA vaccination: a monocentric experience.
Baratè C; Caruso T; Mavilia F; Sammuri P; Pratesi F; Motta G; Guerri V; Galimberti S; Migliorini P
Clin Exp Med; 2023 Aug; 23(4):1197-1203. PubMed ID: 36074205
[TBL] [Abstract][Full Text] [Related]
8. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
[TBL] [Abstract][Full Text] [Related]
9. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
[TBL] [Abstract][Full Text] [Related]
10. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
11. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A
Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660
[TBL] [Abstract][Full Text] [Related]
13. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
14. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
[TBL] [Abstract][Full Text] [Related]
16. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
17. Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren HG; Hansson L; Sallberg Chen M; Buggert M; Ingelman-Sundberg HM; Osterborg A
J Hematol; 2023 Aug; 12(4):170-175. PubMed ID: 37692865
[TBL] [Abstract][Full Text] [Related]
18. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
